Mn Services Vermogensbeheer B.V. Lowers Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mn Services Vermogensbeheer B.V. lessened its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 99,400 shares of the medical equipment provider’s stock after selling 500 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Zimmer Biomet were worth $12,097,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ZBH. Fairfield Bush & CO. bought a new stake in Zimmer Biomet during the 1st quarter valued at about $111,000. United Bank boosted its stake in Zimmer Biomet by 4.1% during the 1st quarter. United Bank now owns 11,072 shares of the medical equipment provider’s stock valued at $1,416,000 after purchasing an additional 437 shares during the last quarter. Panagora Asset Management Inc. increased its holdings in shares of Zimmer Biomet by 153.9% in the 1st quarter. Panagora Asset Management Inc. now owns 9,803 shares of the medical equipment provider’s stock worth $1,254,000 after purchasing an additional 5,942 shares in the last quarter. Aviva PLC raised its stake in shares of Zimmer Biomet by 0.4% in the first quarter. Aviva PLC now owns 30,636 shares of the medical equipment provider’s stock worth $3,918,000 after purchasing an additional 137 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its holdings in shares of Zimmer Biomet by 11.2% during the first quarter. Allianz Asset Management GmbH now owns 41,816 shares of the medical equipment provider’s stock valued at $5,348,000 after purchasing an additional 4,224 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 2.4 %

Shares of ZBH opened at $124.48 on Monday. The firm has a market cap of $25.58 billion, a P/E ratio of 25.46, a price-to-earnings-growth ratio of 2.29 and a beta of 1.01. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $149.25. The company has a 50 day simple moving average of $126.73 and a two-hundred day simple moving average of $118.94.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The company had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.93 billion. During the same period in the previous year, the firm posted $1.88 EPS. Zimmer Biomet’s revenue for the quarter was up 6.3% compared to the same quarter last year. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s payout ratio is 19.63%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ZBH. Raymond James raised their price target on shares of Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Canaccord Genuity Group reissued a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a report on Friday, February 23rd. TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a report on Thursday, February 8th. Evercore ISI raised their target price on Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Finally, JPMorgan Chase & Co. upped their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $139.39.

Insider Transactions at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the transaction, the vice president now directly owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.70% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.